Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer

Prostate Cancer Mortality Reduction by Prostate-Specific Antigen–Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)

(2009) Monique J. Roobol et al.   EUROPEAN UROLOGY

Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context

(2009) G. Draisma et al.   JNCI-Journal of the National Cancer Institute

Screening and Prostate-Cancer Mortality in a Randomized European Study

(2009) Fritz H. Schröder et al.   NEW ENGLAND JOURNAL OF MEDICINE

The economic and workload impact of ‘backdoor’ prostate-specific antigen screening on the UK National Health Service: a single-centre experience

(2008) Arputharaj J. Chelladurai et al.   BJU INTERNATIONAL

PSA-based Screening for Prostate Cancer: How Does It Compare with Other Cancer Screening Tests?

(2008) E. David Crawford et al.   EUROPEAN UROLOGY

Bowel, Urinary, and Sexual Problems Among Long-Term Prostate Cancer Survivors: A Population-Based Study

(2008) Floortje Mols et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Validation of Pretreatment Nomograms for Predicting Indolent Prostate Cancer: Efficacy in Contemporary Urological Practice

(2008) Fei Dong et al.   JOURNAL OF UROLOGY